Global Survey Finds CROs Undergoing Major Changes to Speed Clinical Trials
29.10.2019 19:35:00 EET | Business Wire | Press release
Contract research organizations (CROs) are making significant progress in advancing the industrywide move to improve clinical trial performance, according to the Veeva 2019 Unified Clinical Operations Survey: Annual CRO Report, one of the largest-ever surveys of clinical operations professionals globally. The findings from Veeva Systems (NYSE:VEEV) reveal that CROs are eliminating manual processes and modernizing key areas of clinical trial execution to enhance partner collaboration and improve study performance.
Streamlining Trial Collaboration
All CROs surveyed cite the need to streamline information exchange among study partners. Today, CROs share trial data and documents with sponsors and sites in multiple ways, many of which are manual. Email is CROs’ primary method to exchange information with sites and sponsors, and most still use paper shipments and file shares.
CROs say the state of information exchange causes major challenges with tracking and reporting (71%), misfiled or missing documents (59%), and a host of other issues that limit collaboration and compliance.
As a result, CROs are initiating change to simplify information exchange with study partners, which they expect to yield significant benefits, including reduction in manual processes (77%), streamlined collaboration (65%), improved study quality (64%), and faster study execution (64%).
Accelerating Study Start-up
Study start-up is one of the most resource-intensive phases of clinical trials and has the most opportunity to drive greater efficiency and speed. All CROs report significant challenges with study start-up and more than three-quarters use spreadsheets to manage this area.
Site contracting and budgeting is the most cited and fastest growing issue during the study start-up process. The majority of CROs (70%) say it is their top challenge, up 11 percentage points since 2018. It is also among the primary drivers for change.
For most (80%), faster study start-up time is also a primary driver. Majorities say fewer spreadsheets and manual processes (60%), easier collaboration with sponsors and sites (55%), and better resource planning (55%) would also speed the study start-up process.
Increasing Adoption of Advanced Clinical Applications
CROs are adopting more clinical technologies to eliminate manual processes and improve operational performance. The use of RTSM, eTMF, and CTMS systems has increased the most since 2017. In addition, more CROs are adopting purpose-built study start-up applications than sponsors to speed cycle times (35% of CROs vs. 23% of sponsors).
Replacing manual processes with technology for specific functions has created efficiencies, but it has also created silos. Integration (73%) and reporting across multiple applications (64%) are the top two challenges reported as a result of application silos.
CROs cite the need to streamline fragmented clinical processes and systems to improve study execution. All CROs say they need to unify clinical applications (100%). Better visibility and oversight (74%), faster trials (68%), and easier stakeholder collaboration (63%) are the top drivers to unify.
“CROs are leading the industrywide drive to improve execution and collaboration for faster clinical trials,” said Jim Reilly, vice president of Vault Clinical. “As more organizations reduce the manual and fragmented processes that are prevalent today, drug development will become much more streamlined and study partners will improve how they work together throughout the course of a trial.”
The Veeva 2019 Unified Clinical Operations Survey Report: Annual CRO Report examines CROs’ progress toward a unified clinical operating environment by gathering the experiences and opinions of CRO respondents from around the world. This annual research details the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry’s progress toward unifying clinical systems and processes and aligning stakeholders throughout study execution. The full report is available online at veeva.com/eu/CROreport.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 775 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
® 2019 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005858/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Energy Dome and SRP to Add Long-Duration Energy Storage Project to the Grid, Expand Google Collaboration15.6.2026 16:30:00 EEST | Press release
Energy Dome, a leading provider of innovative capacity solutions for utilities and AI infrastructure, and Salt River Project (SRP), a not-for-profit public power utility serving the greater Phoenix metropolitan area, today announced an agreement to add a 19 megawatt (MW), 10-hour carbon dioxide-based (CO2) battery system to the grid. The project is planned to be co-located on the site of SRP’s Coronado Generating Station (CGS) in St. Johns, Arizona, and it will be developed under a 20-year tolling agreement, with Energy Dome owning and operating the facility and SRP dispatching its output. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615027901/en/ Image: Rendering of Energy Dome’s energy storage system located at the Coronado Generating Station site The project is also part of Google and SRP’s innovative collaboration to accelerate deployment of non-lithium-ion long-duration energy storage (LDES) technologies that suppo
SLB Launches Digital Marketplace to Scale AI and Digital Innovation Across Energy15.6.2026 15:15:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced the launch of the SLB Digital Marketplace, a curated digital destination designed to help energy companies rapidly discover and deploy specialized AI agents, domain models, skills, tools, data connectors and digital applications within their existing digital environments. The SLB Digital Marketplace extends the company’s open platform strategy to its Tela™ agentic AI assistant by enabling SLB, partners, independent software vendors (ISVs), developers and customers to bring purpose-built digital capabilities to the energy industry through a single, governed channel. All marketplace offerings are certified against SLB standards for security, interoperability and compatibility before listing. The launch comes as the industry moves toward agentic AI — where software can reason, act and automate across complex technical workflows. As these capabilities proliferate, energy companies will need access to a broader ecosystem of sp
Thales at Eurosatory 2026: Ready today. Ready tomorrow15.6.2026 15:01:00 EEST | Press release
As Eurosatory 2026 opens its doors, Thales is pleased to share with you a complete overview of the announcements that will be made during the first day of this international defense and security show. This document centralises all our news, innovations and partnerships, released on June, 15th, 2026 with direct links to the associated press releases: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615204020/en/ Thales at Eurosatory 2026: Ready today. Ready tomorrow. Thales unveils new AI-powered training data analytics platform to enhance military training.Thales launches next-generation 70mm laser-guided rocket dedicated for counter-drone operations.Thales unveils next-generation Bushmaster Mulga Utility Variant.Thales launches RapidStriker, a complete system for protection against drones.Renault Group and Thales unveil 4 TROOP, an innovative tactical vehicle for future land forces engagements. Thales press releases will b
Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery15.6.2026 15:00:00 EEST | Press release
Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use. The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research and drug discovery activities. Biocytogen’s Boston facility serves as a key hub supporting the company’s expanding portfolio of drug discovery and translational research capabilities. The facility enables a broad range of in vivo studies supporting antibody therapeutics, multispecific antibodies, ADCs, cell therapies, and other innovative biologics programs for pharmaceutical and biotechnology partners worldwide. Through its proprietary BioMice™ platform, Biocytogen has established one of the industry’s most comprehensive collections of genetically engineered disease mo
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 13:00:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
